Editas Medicine

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EDIT and other ETFs, options, and stocks.

About EDIT

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). 

CEO
Gilmore O’Neill
CEOGilmore O’Neill
Employees
87
Employees87
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2013
Founded2013
Employees
87
Employees87

EDIT Key Statistics

Market cap
232.45M
Market cap232.45M
Price-Earnings ratio
-1.31
Price-Earnings ratio-1.31
Dividend yield
Dividend yield
Average volume
2.24M
Average volume2.24M
High today
$2.50
High today$2.50
Low today
$2.36
Low today$2.36
Open price
$2.43
Open price$2.43
Volume
130.84K
Volume130.84K
52 Week high
$4.54
52 Week high$4.54
52 Week low
$0.9101
52 Week low$0.9101

Stock Snapshot

The current Editas Medicine(EDIT) stock price is $2.38, with a market capitalization of 232.45M. The stock trades at a price-to-earnings (P/E) ratio of -1.31.

During the trading session on 2026-03-18, Editas Medicine(EDIT) shares reached a daily high of $2.50 and a low of $2.36. At a current price of $2.38, the stock is +0.8% higher than the low and still -5.0% under the high.

Trading activity shows a volume of 130.84K, compared to an average daily volume of 2.24M.

Over the past 52 weeks, Editas Medicine(EDIT) stock has traded between a high of $4.54 and a low of $0.91.

Over the past 52 weeks, Editas Medicine(EDIT) stock has traded between a high of $4.54 and a low of $0.91.

EDIT News

Nasdaq 16h
Is Editas Medicine Going to $0?

Key Points Editas Medicine has been on fire over the trailing-12-month period. However, the stock has been crushed since 2021, as it has faced plenty of setba...

Is Editas Medicine Going to $0?
Investing.com 6d
Editas Medicine at Barclays Conference: Strategic Focus on CRISPR Innovation - Investing.com

...

Editas Medicine at Barclays Conference: Strategic Focus on CRISPR Innovation - Investing.com

Analyst ratings

45%

of 11 ratings
Buy
45.5%
Hold
36.4%
Sell
18.2%

People also own

Based on the portfolios of people who own EDIT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.